PPARG and Hypertension: Previous study has reported that rosiglitazone administration ameliorated hypertension, improved vascular function and prevented the development of several of the pathophysiological characteristics associated with the rat model of PE.9 Therefore, PPARγ and ANGPTL4 may become potential novel targets for prevention and treatment of PE.